Curetis To Attend Key Investor and Scientific Conferences In The Second Quarter 2018

Curetis / Curetis To Attend Key Investor and Scientific Conferences In The Second Quarter 2018 . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Curetis To Attend Key Investor and Scientific Conferences In The Second Quarter 2018

Amsterdam, the Netherlands, San Diego, CA, USA and Holzgerlingen, Germany, March 26, 2018, 02:00 a.m. EST -- Curetis N.V. (the "Company" and, together with Curetis USA Inc. and Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that the Company is going to attend several industry conferences in the second quarter of 2018.

April:

H.C. Wainwright Global Life Sciences Conference, April 8-9, 2018 - Monte Carlo, Monaco - company presentation and one-on-one investor meetings.

9^th Deutsche Biotechnologietage, April 18-19, 2018 - Berlin, Germany - company presentation and panel discussion.

Kempen Life Sciences Conference, April 18-19, 2018 - Amsterdam, The Netherlands - company presentation and one-on-one investor meetings.

28^th ECCMID 2018, April 21-24, 2018 - Madrid, Spain; IFEMA - Feria de Madrid: Booth 79.

May:

ASM Clinical Virology Symposium, May 6-9, 2018 - West Palm Beach, FL, USA, Palm Beach County Convention Center: booth 223, corporate workshop and poster.

21th Annual MAD-ID Meeting, May 9-12, 2018 - Orlando, FL, USA.

BioEquity Europe, May 14-16 - Ghent, Belgium- company presentation and one-on-one investor meetings.

ATS 2018 - May 18-23, 2018 - San Diego, CA, USA; San Diego Convention Center: booth 605, poster.

June:

ASM Microbe 2018, June 7-11, 2018 - Atlanta, GA USA; Georgia World Congress Center: booth 2323, industry forum, corporate workshop and poster.

Goetzpartners Healthcare Day, June 22, 2018 - London, UK - company presentation and one-on-one investor meetings.

###

About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies, and has entered into several international distribution agreements covering many countries across Europe, the Middle East and Asia.

In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximize the R&D and related scientific and business opportunities of the GEAR assets acquired in 2016 for the entire Curetis Group.

For further information, please visit www.curetis.com.

Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.

The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.

This press release includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis' actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Contact details

Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com or ir@curetis.com
www.curetis.com - www.unyvero.com

International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth@theruthgroup.com
Tel. +1 646 536 7012

--- End of Message ---

Curetis
Max-Eyth-Str. 42 Holzgerlingen Germany


Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;